

# AmoyDx PCR

## Solutions

AmoyDx

Better life with AmoyDx

**Amoy Diagnostics Co., Ltd.**

Email: [sales@amoydx.com](mailto:sales@amoydx.com)  
Add: 39 Dingshan Road,  
Xiamen 361027, China


Tel: (86) 592-6806835  
Fax: (86) 592-6806839



[www.amoydx.com](http://www.amoydx.com)




# Content



|                             |    |
|-----------------------------|----|
| Technical Platform          | 1  |
| ADx-ARMS® Technology.....   | 1  |
| Super-ARMS® Technology..... | 2  |
| RT-PCR Technology.....      | 3  |
| Products for Diagnostics    | 4  |
| Lung Cancer.....            | 4  |
| Colorectal Cancer.....      | 6  |
| Cervical Cancer.....        | 8  |
| Leukemia .....              | 9  |
| DNA/RNA Extraction.....     | 10 |
| Ordering Information        | 11 |

## ADx-ARMS® Technology



### Key words

#### Mature


Form 2008 to 2019, ADx-ARMS technology benefits over 1,400,000 patients, and supported investigators to publish more than 110 SCI articles.

#### Reliable

ADx-ARMS has maintained the most widely used technology for 6 consecutive years (2014~2019) in EMQN external quality assessment scheme for lung cancer, with the highest accuracy of 99.53%.




Proportion of Commercial Test Methods EMQN for Lung Cancer (2014-2019)



#### Easy-to-use

Follow the standard qPCR procedure, get results within 90 minutes.



## Super-ARMS® Technology

### A new revolution on qPCR platform

Compared to ADx-ARMS®, Super-ARMS® technology, by optimizing the PCR reaction system, primer/probe design, product structure and results interpretation, achieves a sensitivity up to 0.2% while maintaining high specificity.

### Key words

#### High analytical sensitivity

Sensitivity up to 0.2%.




#### High clinical sensitivity<sup>[1]</sup>

Super-ARMS® EGFR shows impressive sensitivity and specificity in clinical practice.

| EGFR Mutation      | Tumor Tissue |           |           |            |
|--------------------|--------------|-----------|-----------|------------|
|                    | +            | -         | Total     |            |
| Plasma             | +            | 50        | 0         | 50         |
|                    | -            | 11        | 48        | 59         |
|                    | <b>Total</b> | <b>61</b> | <b>48</b> | <b>109</b> |
| <b>Sensitivity</b> | <b>82.0%</b> |           |           |            |
| <b>Specificity</b> | <b>100%</b>  |           |           |            |

#### High predictive value for drug response<sup>[2]</sup>

In AURA 17 study, patients with positive EGFR T790M mutation tested by Super-ARMS® EGFR achieved the highest objective response rate (ORR) during treatment with osimertinib.




[1] Li Y, Xu H, Su S, Ye J, Chen J, Jin X, et al. PLoS ONE 12(8): e0183331.

[2] C Zhou, YL Wu, et al., EMSO 1331P.

## RT-PCR Technology

Reverse Transcription PCR (RT-PCR) analyzes gene alterations based on tumor mRNA, which includes two processes: reverse transcription of target RNA to generate cDNA and PCR amplification of target cDNA to detect gene alterations with specific primers and fluorescent probes.

### Work flow



### Key words

#### Objective

Interpret results by Ct values.

#### High sensitivity

Limit of detection is 125 copies/ rxn.

#### Multi-sample choice

Work with RNA from FFPE, FNA and cytology samples.

#### Global recognition<sup>[1]</sup>

Based on the biggest ROS1 clinical trial worldwide, AmoyDx ROS1 kit has been approved by MHLW\* in Japan and MFDS\*\* in South Korea as a companion diagnostic for crizotinib in Japan and Korea.




Fig. Best percent change in the target tumor burden from baseline as assessed by independent radiology review. Number of patients is based on the response-evaluable population that excludes early death, indeterminate, and patients with non-target lesions only.

[1] K. Goto, et al. 2016 ASCO Abstract 9022. \* Ministry of Health, Labour and Welfare \*\* The Ministry of Food and Drug Safety

## Lung Cancer

Numerous oncogene alterations have been identified to be important for lung cancer pathogenesis and impact therapy selection, including EGFR, ALK, ROS1, BRAF, MET, HER2, RET, etc. Testing of non-small cell lung cancer (NSCLC) for multiple gene mutations is vital for identification of potentially efficacious targeted therapies.

| Gene | Alteration                | Frequency in NSCLC | Available Targeted Therapy                               |
|------|---------------------------|--------------------|--|
| EGFR | Mutation                  | 10~35%             | Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib |
| ALK  | Fusion                    | 3~7%               | Crizotinib, Alectinib, Ceritinib, Brigatinib             |
| ROS1 | Fusion                    | 2%                 | Crizotinib, Ceritinib, Entrectinib                       |
| BRAF | Mutation                  | 1~4%               | Trametinib, Dabrafenib                                   |
| MET  | Exon 14 skipping mutation | 3%                 | Tepotinib, Capmatinib, Crizotinib                        |
| HER2 | Mutation                  | 2~4%               | Ado-trastuzumab emtasine                                 |
| RET  | Fusion                    | 1%                 | Selpercatinib, Cabozantinib, Vandetanib                  |
| NTRK | Fusion                    | 1%                 | Larotrectinib, Entrectinib                               |
| KRAS | G12C mutation             | 11~16%             | AMG510, MRTX849  |

### AmoyDx® Pan Lung Cancer PCR Panel

|               |  |                    |                              |
|---------------|--|--------------------|------------------------------|
| Gene          | EGFR / KRAS / BRAF / HER2 / ALK / ROS1 / RET / MET / NTRK1 / NTRK2 / NTRK3 | Alteration         | 167 Variants                 |
| Qualification | CE-IVD   | Limit of Detection | RNA: 125 cp/rxn<br>DNA: 1~5% |

### AmoyDx® Multi-Gene Mutations Detection Kit

|               |  |                    |                            |
|---------------|--|--------------------|----------------------------|
| Gene          | EGFR / KRAS / BRAF / NRAS / PIK3CA / HER2 / ALK / ROS1 / RET | Alteration         | 118 Variants               |
| Qualification | CE-IVD, NMPA   | Limit of Detection | RNA: 450 cp/rxn<br>DNA: 1% |

### Super-ARMS® EGFR Mutation Detection Kit

|               |               |                    |              |
|---------------|---------------|--------------------|--------------|
| Gene          | EGFR          | Alteration         | 42 Mutations |
| Coverage      | 99.03%        | Limit of Detection | 0.2~0.8%     |
| Qualification | CE-IVD, NMPA* |                    |              |

\*National Medical Products Administration (China)

### Super-ARMS® EGFR T790M Mutation Detection Kit

|               |        |                    |                |
|---------------|--------|--------------------|----------------|
| Gene          | EGFR   | Alteration         | T790M Mutation |
| Coverage      | -      | Limit of Detection | 0.2%           |
| Qualification | CE-IVD |                    |                |

### AmoyDx® EGFR 29 Mutations Detection Kit

|               |              |                    |              |
|---------------|--------------|--------------------|--------------|
| Gene          | EGFR         | Alteration         | 29 Mutations |
| Coverage      | 98.43%       | Limit of Detection | 1%           |
| Qualification | CE-IVD, NMPA |                    |              |

### AmoyDx® EML4-ALK Fusion Gene Detection Kit

|               |              |                    |            |
|---------------|--------------|--------------------|------------|
| Gene          | EML4-ALK     | Alteration         | 21 Fusions |
| Coverage      | ~90%         | Limit of Detection | 125 cp/rxn |
| Qualification | CE-IVD, NMPA |                    |            |

### AmoyDx® ROS1 Gene Fusions Detection Kit

|               |                          |                    |            |
|---------------|--------------------------|--------------------|------------|
| Gene          | ROS1                     | Alteration         | 14 Fusions |
| Coverage      | ~99%                     | Limit of Detection | 125 cp/rxn |
| Qualification | CE-IVD, NMPA, MHLW, MFDS |                    |            |

### AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit

|               |              |                    |                                 |
|---------------|--------------|--------------------|---------------------------------|
| Gene          | ALK, ROS1    | Alteration         | 26 ALK Fusions, 14 ROS1 Fusions |
| Coverage      | ~95%         | Limit of Detection | 125 cp/rxn                      |
| Qualification | CE-IVD, NMPA |                    |                                 |

### AmoyDx® RET Gene Fusions Detection Kit

|               |        |                    |            |
|---------------|--------|--------------------|------------|
| Gene          | RET    | Alteration         | 9 Fusions  |
| Qualification | CE-IVD | Limit of Detection | 125 cp/rxn |

### AmoyDx® EGFR/ALK/ROS1 Mutations Detection Kit

|               |                 |                    |  |
|---------------|-----------------|--------------------|--|
| Gene          | EGFR, ALK, ROS1 | Alteration         | 24 EGFR Mutations<br>21 ALK Fusions<br>13 ROS1 Fusions |
| Qualification | CE-IVD, NMPA    | Limit of Detection | DNA: 1%<br>RNA: 125 cp/rxn                             |

### AmoyDx® MET Mutation Detection Kit

|               |        |                    |                           |
|---------------|--------|--------------------|---------------------------|
| Gene          | MET    | Alteration         | Exon 14 skipping mutation |
| Qualification | CE-IVD | Limit of Detection | 500 cp/rxn                |

### AmoyDx® HER2 Mutation Detection Kit

|               |      |                    |              |
|---------------|------|--------------------|--------------|
| Gene          | HER2 | Alteration         | 13 mutations |
| Qualification | RUO  | Limit of Detection | 1%           |

### AmoyDx® NTRK Gene Fusions Detection Kit

|               |                   |                    |                |
|---------------|-------------------|--------------------|----------------|
| Gene          | NTRK1/NTRK2/NTRK3 | Alteration         | 109 Fusions    |
| Qualification | RUO               | Limit of Detection | 125-250 cp/rxn |

## Colorectal Cancer

Somatic mutations involve such genes as KRAS, NRAS, BRAF and PIK3CA have been known to be prognostic or predictive markers for specific therapies available in colorectal cancer. In total, somatic KRAS, NRAS and PIK3CA mutations occur in 20~50%, 1~6%, 10~30% of colorectal cancers respectively. And the most common BRAF mutations are V600 mutations in exon 15, which occur in 8~15% of colorectal cancers.

Patients without any known RAS mutations (exon 2, 3, 4) could benefit from Erbitux (cetuximab) or Vectibix (panitumumab). BRAF and PIK3CA mutations make response to cetuximab or panitumumab highly unlikely. Patients with metastatic colorectal cancer should have tumor tissue genotyped for RAS (KRAS and NRAS) and BRAF mutations.

### AmoyDx® KRAS Mutation Detection Kit

|               |              |                    |              |
|---------------|--------------|--------------------|--------------|
| Gene          | KRAS         | Alteration         | 19 Mutations |
| Coverage      | >97.74%      | Limit of Detection | 1~5%         |
| Qualification | CE-IVD, NMPA |                    |              |

### AmoyDx® NRAS Mutation Detection Kit

|               |              |                    |              |
|---------------|--------------|--------------------|--------------|
| Gene          | NRAS         | Alteration         | 16 Mutations |
| Coverage      | >87.37%      | Limit of Detection | 1~5%         |
| Qualification | CE-IVD, NMPA |                    |              |

### AmoyDx® BRAF V600 Mutations Detection Kit

|               |              |                    |                  |
|---------------|--------------|--------------------|------------------|
| Gene          | BRAF         | Alteration         | 6 V600 Mutations |
| Coverage      | 95%          | Limit of Detection | 1%               |
| Qualification | CE-IVD, NMPA |                    |                  |

### AmoyDx® KRAS/NRAS Mutations Detection Kit

|               |              |                    |  |
|---------------|--------------|--------------------|--|
| Gene          | KRAS, NRAS   | Alteration         | 19 KRAS Mutations<br>13 NRAS Mutations |
| Qualification | CE-IVD, NMPA | Limit of Detection | 1~5%                                   |

### AmoyDx® KRAS/NRAS/BRAF Mutations Detection Kit

|               |                  |                    |   |
|---------------|------------------|--------------------|---|
| Gene          | KRAS, NRAS, BRAF | Alteration         | 17 KRAS Mutations<br>13 NRAS Mutations<br>1 BRAF Mutation |
| Qualification | CE-IVD, NMPA     | Limit of Detection | 1~5%  |

### Super-ARMS® KRAS/NRAS/BRAF Mutations Detection Kit

(Minimum Order Quantity required)

|               |                  |                    |  |
|---------------|------------------|--------------------|--|
| Gene          | KRAS, NRAS, BRAF | Alteration         | 18 KRAS Mutations<br>15 NRAS Mutations<br>6 BRAF Mutations |
| Qualification | CE-IVD           | Limit of Detection | 0.2~1%   |

### AmoyDx® PIK3CA Rive Mutations Detection Kit

|               |              |                    |             |
|---------------|--------------|--------------------|-------------|
| Gene          | PIK3CA       | Alteration         | 5 Mutations |
| Qualification | CE-IVD, NMPA | Limit of Detection | 1~2%        |

### AmoyDx® PIK3CA Mutation Detection Kit

|               |        |                    |              |
|---------------|--------|--------------------|--------------|
| Gene          | PIK3CA | Alteration         | 11 Mutations |
| Qualification | RUO    | Limit of Detection | 1~2%         |

## Cervical Cancer

Human papillomavirus (HPV) is a sexually transmitted DNA virus that establishes infection in squamous epithelial cells in the human body. There are more than 200 types of HPV, which can be classified into high or low-risk types depending upon their oncogenic potentials. High-risk HPVs are also called oncogenic HPVs, which have been confirmed to cause cancer. Low-risk HPVs can cause genital warts and low-grade changes in the cells, but rarely cause cancer.

Virtually all cervical cancers are caused by high-risk HPV infections. Approximately 99.7% of cervical cancers are caused by high-risk HPV infection. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases.

|                                     |  |
|-------------------------------------|--|
| The most common high-risk HPV types | Other high-risk HPV types                  |
| 16, 18                              | 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 |
| Probably high-risk HPV types        | The most common low-risk HPV types         |
| 26, 53, 66, 70, 73, 82              | 6, 11                                      |

### AmoyDx® HPV Detection Kit

(Minimum Order Quantity required)

|                | Detecting Capability  | Kit Format                               | Limit of Detection   |
|----------------|---|--|--|
| High-risk HPV  | HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, and 82   | 1 reaction tube, 3 fluorescents labeled  | HPV16: 1000 cp/rxn, HPV45, 53, 59, 73: 50 cp/rxn, Other HPVs: 500 cp/rxn |
| HPV Genotyping | 19 High-risk HPVs: HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82<br>2 Low-risk HPVs: HPV6, 11 | 8 reaction tubes, 3 fluorescents labeled | 100 cp/rxn   |

## Leukemia

Leukemia is characterized by the abnormal proliferation of blood precursor cells of myeloid or lymphoid origin. There are four types of leukemia - acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). Recently, biomarkers of different leukemia subtypes based on genetic have been reported, such as JAK2, C-KIT, BCR-ABL, etc.

### AmoyDx® JAK2 Mutation Detection Kit

|                      |        |                           |                |
|----------------------|--------|---------------------------|----------------|
| <b>Gene</b>          | JAK2   | <b>Alteration</b>         | V617F Mutation |
| <b>Qualification</b> | CE-IVD | <b>Limit of Detection</b> | 1%             |

## DNA/RNA Extraction

### AmoyDx® DNA/RNA Extraction Kits


#### Highlights

- **Simple and quick**
- **High purity and high yield**
- **Simultaneous DNA & RNA**
- **Good and stable PCR results**

#### Sample types

FFPE tissue, fresh and frozen tissue, pleural effusion, whole blood, serum, plasma, cytology sample.

#### Principle and Procedure



#### Performance \*

| Kit (FFPE RNA)    | A260                | A260/A280           | RNA Conc. (ng/ul)        | Ct Value **            |
|-------------------|---------------------|---------------------|--------------------------|------------------------|
| <b>AmoyDx</b>     | 2.72<br>(0.84~3.56) | 1.91<br>(1.89~1.93) | 106.24<br>(33.78~142.53) | 23.62<br>(21.70~25.55) |
| <b>Competitor</b> | 1.62<br>(0.76~2.47) | 1.92<br>(1.88~1.96) | 64.74<br>(30.51~98.98)   | 24.05<br>(21.36~26.74) |

\* The data is from GC Lab in South Korea.

\*\* The samples were extracted RNA using both AmoyDx and competitor's kit, and the Ct values were obtained in ROS1 gene fusion testing.

## Ordering Information

The Cat. No. marked with "\*" requires minimum purchase quantity, please consult your account manager or distributor before order placing.

| Kit                           | Cat. No.        | Specification | Validated Instruments   |
|-------------------------------|-----------------|---------------|---|
| <b>Super-ARMS® EGFR</b>       | 8.01.20213X012E | 12 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, SLAN-96S, Rotor-Gene Q (36 wells), Cobas® z480               |
| <b>Super-ARMS® EGFR T790M</b> | 8.01.20212X024D | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, SLAN-96S   |
| <b>ADx-ARMS® EGFR</b>         | 8.01.20201W010A | 10 tests/kit  | Mx3000P, ABI7300, ABI7500, ABI7900HT  |
|                               | 8.01.20201W010B | 10 tests/kit  | LightCycler480 II, Bio-Rad CFX96, Cobas® z480   |
|                               | 8.01.20201W010D | 10 tests/kit  | SLAN-96S  |
|                               | 8.01.20201X024E | 24 tests/kit  | Mx3000P, ABI7300, ABI7500, ABI7900HT, ABI StepOnePlus, LightCycler480 II, Bio-Rad CFX96, SLAN-96S |
|                               | 8.01.20201X024F | 24 tests/kit  | Rotor-Gene Q/6000 (72 wells)  |
| <b>EML4-ALK</b>               | 8.01.22001X024H | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, Bio-Rad CFX 96, Rotor-Gene Q/6000 (72 wells), SLAN-96S       |
| <b>ROS1</b>                   | 8.01.23201W012A | 12 tests/kit  | Mx3000P, ABI7500  |
|                               | 8.01.23201X012H | 12 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, Bio-Rad CFX 96, Rotor-Gene Q/6000 (72 wells), SLAN-96S       |
| <b>ALK/ROS1</b>               | 8.01.24401W008A | 8 tests/kit   | Mx3000P, ABI7500  |
|                               | 8.01.24401W008B | 8 tests/kit   | LightCycler480 II   |
|                               | 8.01.24401W008D | 8 tests/kit   | SLAN-96S  |

## Ordering Information

| Kit                  | Cat. No.        | Specification | Validated Instruments  |
|----------------------|-----------------|---------------|--|
| <b>EGFR/ALK/ROS1</b> | 8.01.25501W008A | 8 tests/kit   | Mx3000P  |
|                      | 8.01.25501W008D | 8 tests/kit   | SLAN-96S   |
|                      | 8.01.25501W008J | 8 tests/kit   | ABI7500  |
| <b>RET Fusion</b>    | 8.01.23301X012H | 12 tests/kit  | Mx3000P, ABI 7500, LightCycler480 II, Bio-Rad CFX96, Rotor-Gene Q/6000 (72 wells)  |
| <b>HER2</b>          | 8.01.26801X024H | 24 tests/kit  | Stratagene Mx3000P™, ABI 7500, ABI 7900HT, ABI StepOnePlus, LightCycler 480, Bio-Rad CFX96, Rotor-Gene Q/6000 (72 wells), SLAN-96S |
| <b>Multi-Gene</b>    | 8.01.26301W006A | 6 tests/kit   | Stratagene Mx3000P™  |
|                      | 8.01.26301W006B | 6 tests/kit   | LightCycler480 II, Cobas® z480   |
|                      | 8.01.26301W006D | 6 tests/kit   | SLAN-96S   |
|                      | 8.01.26301W006J | 6 tests/kit   | ABI 7500   |
| <b>Pan LC Panel</b>  | 8.0131202W008J  | 8 tests/kit   | QuantStudio 5  |
|                      | 8.0131202W008B  | 8 tests/kit   | LightCycler480 II  |
| <b>MET Skipping</b>  | 8.01.26101X024H | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, SLAN-96S, Rotor-Gene Q(72 wells)  |
| <b>KRAS</b>          | 8.01.20102W006A | 8 tests/kit   | Mx3000P, ABI7500   |
|                      | 8.01.20102W006B | 8 tests/kit   | LightCycler480 II, Cobas® z480   |
|                      | 8.01.20102X024H | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, Bio-Rad CFX96, Rotor-Gene Q/6000 (72 wells), SLAN-96S   |
| <b>NRAS</b>          | 8.01.25001W008A | 8 tests/kit   | Mx3000P, ABI7500   |
|                      | 8.01.25001X024H | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, Bio-Rad CFX96, SLAN-96S   |



## Ordering Information

| Kit                                | Cat. No.         | Specification | Validated Instruments  |
|------------------------------------|------------------|---------------|--|
| <b>BRAF</b>                        | 8.01.20302X024E  | 24 tests/kit  | Mx3000P, ABI7500, ABI7900HT, ABI StepOnePlus, LightCycler480 II, Bio-Rad CFX96, SLAN-96S   |
| <b>BRAF V2</b>                     | 8.0120303X024E*  | 24 tests/kit  | 3000P, SLAN-96S, Rotor-Gene Q (72 wells)   |
|                                    | 8.0120303X024B*  | 24 tests/kit  | LightCycler480 II  |
|                                    | 8.0120303X024C*  | 24 tests/kit  | Bio-Rad CFX96  |
| <b>KRAS/NRAS</b>                   | 8.01.25402W006A  | 6 tests/kit   | Mx3000P, ABI7500   |
|                                    | 8.01.25402W006D  | 6 tests/kit   | SLAN-96S   |
|                                    | 8.01.25402X024H  | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480 II, Bio-Rad CFX96, Rotor-Gene Q/6000 (72 wells), SLAN-96S |
| <b>KRAS/NRAS/BRAF</b>              | 8.01.25403W006A  | 6 tests/kit   | Mx3000P, ABI7500   |
|                                    | 8.01.25403W006B* | 6 tests/kit   | LightCycler480 II  |
|                                    | 8.01.25403W006D  | 6 tests/kit   | SLAN-96S   |
| <b>Super-ARMS® KRAS/NRAS /BRAF</b> | 8.01.25404X024E* | 24 tests/kit  | Mx3000P, ABI7500, SLAN-96S   |
| <b>PIK3CA</b>                      | 8.01.21601X024E  | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480, Bio-Rad CFX96, SLAN-96S                                  |
|                                    | 8.0121601X012F   | 12 tests/kit  | Rotor-Gene Q/6000 (72 wells)   |
| <b>PIK3CA 11</b>                   | 8.0121602X024E   | 24 tests/kit  | Mx3000P, ABI7500, LightCycler480, Bio-Rad CFX96, SLAN-96S                                  |
| <b>NTRK Fusion</b>                 | 8.0126001X024E   | 24 tests/kit  | Stratagene Mx3000P™, ABI7500, QuantStudio 5, LightCycler480 II, SLAN-96S                   |
| <b>HPV High-risk</b>               | 8.01.25802X048E  | 48 tests/kit  | Mx3000P, ABI 7500, LightCycler480, Bio-Rad CFX96, SLAN-96S, Rotor Gene Q/6000 (72 wells)   |
| <b>HPV Genotyping</b>              | 8.01.25803X048E  | 48 tests/kit  | Mx3000P, ABI 7500, SLAN-96S LightCycler480 II, Bio-Rad CFX96                               |

## Ordering Information

| Kit                       | Cat. No.        | Specification | Validated Instruments   |
|---------------------------|-----------------|---------------|---|
| <b>TERT/HRAS</b>          | 8.01.27701X024B | 24 tests/kit  | ABI7500, LightCycler480 II  |
|                           | 8.01.27701X024D | 24 tests/kit  | Mx3000P, SLAN-96S   |
| <b>JAK2</b>               | 8.01.20801X024E | 24 tests/kit  | Mx3000P, ABI 7500, ABI7900HT, ABI StepOnePlus, LightCycler480 II, Bio-Rad CFX96 |
| <b>FFPE DNA</b>           | 8.02.23501X036G | 36 tests/Kit  |   |
| <b>FFPE RNA</b>           | 8.02.24101X036G | 36 tests/Kit  |   |
| <b>FFPE DNA/RNA</b>       | 8.02.23601X036G | 36 tests/Kit  |   |
| <b>Circulating DNA</b>    | 8.02.26201X024G | 24 tests/Kit  |   |
| <b>Blood DNA</b>          | 8.02.24201X036G | 36 tests/Kit  |   |
| <b>Tissue DNA</b>         | 8.02.24301X036G | 36 tests/Kit  |   |
| <b>Tissue RNA</b>         | 8.02.24601X036G | 36 tests/Kit  |   |
| <b>Cell-free DNA Tube</b> | 8.04.26401X010G | 10 tests/Kit  |   |

